YARW — Yarrow Bioscience, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1566044 ·
Last close
$14.21
Market Cap
$163.04M
52W High
$44.28
52W Low
$9.65
ADV30
171,315
Next earnings
—
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 97,000 — -3,102,000 -3,007,000 23,604,000 22,925,000 1,542,000
Mar 2026 0 — -2,862,000 -2,745,000 27,950,000 26,351,000 1,527,000
Dec 2025 0 — -994,000 -70,994,000 — — —

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,933,000
Investing CF
—
Financing CF
$99,854,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4809.14
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-764,245,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-14,500,000
Pretax Income TTM
$-82,385,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 1y)

Revenues vs Net Income (last 1y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 — — — 100,407,000 71,547,000 28,860,000 —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$23,604,000
Forward EPS
$-1.65

Peers — same industry

TickerNameMarket CapLastDaily %
PRQR ProQR Therapeutics N.V. $162.29M $1.15 —
BCYC BICYCLE THERAPEUTICS PLC $162.10M $3.20 —
ANTX AN2 Therapeutics, Inc. $160.50M $4.23 —
ABEO ABEONA THERAPEUTICS INC. $160.27M $2.60 —
ELDN Eledon Pharmaceuticals, Inc. $167.23M $1.98 —

News headlines (Yahoo Finance, 1h cache)

Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:00 · Yahoo
Guggenheim starts Yarrow Bioscience at Buy, citing Graves’ disease potential
2026-11-06 17:08 · Yahoo
Yarrow Bioscience Announces Participation in November Investor Events
2026-11-02 12:00 · Yahoo
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-09-14 20:05 · Yahoo
Yarrow Bioscience Announces Proposed Underwritten Public Offering
2026-09-10 20:03 · Yahoo
Molson Coors downgraded, SiTime upgraded: Wall Street's top analyst calls
2026-11-06 15:07 · Yahoo
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
2026-09-11 01:11 · Yahoo
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 11:00 · Yahoo
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye D
2026-07-27 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.